Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Tiziana Life Sciences Ltd.
< Previous
1
2
Next >
Tiziana Life Sciences Appoints New Chief Executive Officer
August 19, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
August 14, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Granted FDA Fast Track Designation
July 24, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Receives $3.4 Million in Non-Dilutive Funding
June 28, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
June 26, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
June 11, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
June 06, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
May 30, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
May 13, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
April 23, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
April 22, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
April 19, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 18, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
April 11, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
January 08, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
January 05, 2024
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
December 19, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
December 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
November 30, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
November 01, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
October 18, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
October 16, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
October 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tickers
TLSA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.